Health Times of Rhode Island
SEE OTHER BRANDS

Your health and wellness news from Rhode Island

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

Press releases published on August 28, 2025

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it …

NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

TORONTO and HAIFA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

 Scottish Medtech Seluna Launches Pediatric Sleep Trial Ahead of U.S. Entry

Scottish Medtech Seluna Launches Pediatric Sleep Trial Ahead of U.S. Entry

Glasgow, UK, Aug. 28, 2025 (GLOBE NEWSWIRE) --       Scottish Medtech Seluna Launches Pediatric Sleep Trial Ahead of U.S. Entry Seluna seeks US collaborations and investment to transform childhood sleep disorder diagnosis globally Scotland-based medtech …

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, …

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price …

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …

Tidewave Bio Completes FDA INTERACT Meeting for TBC-1, a Universal Cell Therapy Platform in Solid Tumors

Tidewave Bio Completes FDA INTERACT Meeting for TBC-1, a Universal Cell Therapy Platform in Solid Tumors

LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, off-the-shelf, gene-enhanced antigen-presenting cell therapy platform, today announced the successful completion of its FDA INTERACT meeting. This …

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …

Merus to Present at the 2025 Wells Fargo Healthcare Conference

Merus to Present at the 2025 Wells Fargo Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor …

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to …

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025 …

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and …

Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in …

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in …

Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held in New York, …

Introducing ECP Engage: Marketing services tailored exclusively for optometry practices

Introducing ECP Engage: Marketing services tailored exclusively for optometry practices

Toronto, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marketing plays a crucial role in growing an eye care practice and supporting patients. Today, digital-first PR firm Anamorphiq is launching a new service designed to help. ECP Engage is a suite of marketing …

Catheter Precision Announces First Procedures in France as LockeT Expansion Continues

Catheter Precision Announces First Procedures in France as LockeT Expansion Continues

FORT MILL, S.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company and leader in innovative cardiac electrophysiology solutions, is proud to announce the first LockeT procedures in France. …

LifeMD to Participate in Three Investor Conferences During September

LifeMD to Participate in Three Investor Conferences During September

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September: Cantor …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions